Most industry insiders did not expect Aetna to pour cold water on Obamacare.
Industry and regulatory fixes to the ACA marketplaces appear inevitable as impatience and losses escalate.
Aetna soured on its ACA business after claims data showed higher use of pricey specialty drugs. The company expects to lose $300 million on the marketplace this year and won’t expand its exchange footprint in 2017.